Compare Stocks → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AMTOTCMKTS:LXXGF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMTAmerican Tower$197.40+1.7%$196.36$154.58▼$219.10$90.52B0.682.45 million shs2.49 million shsLXXGFLexaGene0.08-16.5%0.080.05▼0.25N/AN/A318,206 shs1.42 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMTAmerican Tower+1.70%+1.42%+5.16%-9.11%+2.35%LXXGFLexaGene0.00%0.00%-0.49%-0.49%-0.49%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMTAmerican Tower4.8749 of 5 stars2.54.04.23.13.32.51.9LXXGFLexaGeneN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMTAmerican Tower2.91Moderate Buy$217.5510.21% UpsideLXXGFLexaGeneN/AN/AN/AN/ACurrent Analyst RatingsLatest LXXGF, 4DX, ADR, and AMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$224.00 ➝ $234.002/28/2024AMTAmerican TowerBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$235.00 ➝ $228.002/28/2024AMTAmerican TowerJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$236.00 ➝ $230.001/24/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$229.00 ➝ $224.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMTAmerican Tower$11.14B8.26$10.08 per share19.59$23.30 per share8.47LXXGFLexaGeneN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMTAmerican Tower$1.48B$3.1862.0818.731.3413.31%12.80%2.24%4/24/2024 (Estimated)LXXGFLexaGeneN/AN/A0.00∞N/AN/AN/AN/AN/ALatest LXXGF, 4DX, ADR, and AMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/202412/31/2023AMTAmerican Tower$2.10$0.94-$1.16$0.18$2.74 billion$2.79 billion DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMTAmerican Tower$6.803.44%+12.50%213.84%12 YearsLXXGFLexaGeneN/AN/AN/AN/AN/ALatest LXXGF, 4DX, ADR, and AMT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/14/2024AMTAmerican Towerquarterly$1.623.3%4/11/20244/12/20244/26/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMTAmerican Tower3.290.690.69LXXGFLexaGeneN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMTAmerican Tower92.69%LXXGFLexaGeneN/AInsider OwnershipCompanyInsider OwnershipAMTAmerican Tower0.24%LXXGFLexaGeneN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMTAmerican Tower5,643466.35 million465.23 millionOptionableLXXGFLexaGene41N/AN/ANot OptionableLXXGF, 4DX, ADR, and AMT HeadlinesSourceHeadlineBeijing Bohui Innovation Biotechnology Group Co Ltd Class Amorningstar.com - May 31 at 2:19 PMClosing Bell: Lexagene Holdings Inc down on Tuesday (LXG)theglobeandmail.com - April 20 at 8:51 PMLexaGene Holdings files for bankruptcymsn.com - February 24 at 11:51 PMLexaGene Holdings Inc: LexaGene Files for Chapter 7 Bankruptcyfinanznachrichten.de - February 24 at 6:51 PMLexaGene Files for Chapter 7 Bankruptcyfinance.yahoo.com - February 24 at 6:51 PMLexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customersfinance.yahoo.com - January 18 at 10:08 AMBioPharma Engages LexaGene in Second Feasibility Studyfinance.yahoo.com - December 16 at 8:19 AMLexaGene Successfully Completes Statement of Work for BioPharma Companyfinance.yahoo.com - November 22 at 4:30 PMLexaGene Closes Secured Convertible Note Transactionfinance.yahoo.com - November 1 at 11:27 PMLexaGene Closes Secured Convertible Note Transactionfinance.yahoo.com - November 1 at 11:27 PMLexaGene Holdings Proposes to Amend Warrants Termsfinance.yahoo.com - October 27 at 8:00 PMLexaGene Enters into Secured Convertible Note Agreementfinance.yahoo.com - October 24 at 9:14 AMLarge Biopharma Company Engages LexaGene in Statement of Work to Expedite Technology Validationfinance.yahoo.com - October 20 at 8:06 AMLXXGF LexaGene Holdings Inc.seekingalpha.com - October 15 at 6:49 PMLexaGene Receives Signed Quote from Large Biopharma Company to Purchase a MiQLab Systemfinance.yahoo.com - October 13 at 11:34 AMLexaGene Announces MiQLab® System Sale to Veterinary Hospital in Californiafinance.yahoo.com - September 1 at 8:37 AMLexaGene Verifies CDC Monkeypox Assay Works on MiQLab System and Readies Company Should an EUA be Declaredfinance.yahoo.com - August 29 at 10:26 AMLexaGene's MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistrystockhouse.com - August 26 at 4:08 AMLexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistryfinance.yahoo.com - August 24 at 11:34 AMUniversity of Pennsylvania's School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene's MiQLab Systemstockhouse.com - August 18 at 7:42 PMUniversity of Pennsylvania’s School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene’s MiQLab Systemfinance.yahoo.com - August 17 at 8:35 AMLexaGene Reduces Time-to-Result by ~35%finance.yahoo.com - August 10 at 12:02 PMLexaGene Announces Filing of Financial Statements, Revocation of MCTO & the Granting of Incentive Equity Awards to Employeesfinance.yahoo.com - July 29 at 9:03 AMLexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infectionsfinance.yahoo.com - July 27 at 9:57 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAmerican TowerNYSE:AMTAmerican Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.LexaGeneOTCMKTS:LXXGFLexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.